

CIRM Funded Clinical Trials

AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205

Disease Area:	Blood Cancer
Investigator:	Edward Kavalerchik
Institution:	Angiocrine Bioscience, Inc.
CIRM Grant:	CLIN2-11371
Award Value:	\$6,192,579
Trial Sponsor:	Angiocrine Bioscience, Inc.
Trial Stage:	Phase 1
Trial Status:	Launching
Targeted Enrollment:	N/A



Edward Kavalerchik

Details:

Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system.

Design:

First in human, Phase 1, multi-center trial

Goal:

Safety

News about this clinical trial:

Stem Cell Agency Board approves 50th clinical trial

Source URL: <https://www.cirm.ca.gov/clinical-trial/ab-205-001-phase-1b-trial-and-related-activities-support-clinical-development-ab-205>